Genscript Biotech (HK:1548) has released an update.
Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of multiple myeloma, providing promising data from the Phase 3 CARTITUDE-4 trial. Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth opportunities for investors in the biopharmaceutical sector.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Computer (SMCI) Says Special Committee Found No Evidence of Fraud
- Netflix’s France and Netherlands Offices Raided for Possible Tax Fraud
- Class Action Lawsuit Against Bumble Inc. (NASDAQ:BMBL)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
